Summary of Bruker (BRKR) 2025 Conference Call Company Overview - **Company**: Bruker Corporation (BRKR) - **Event**: 2025 Conference Call held on June 04, 2025 Key Industry Insights - **Industry**: Mass Spectrometry and Proteomics - **Market Trends**: The mass spectrometry market is experiencing significant innovation, particularly in proteomics and metabolomics, with a focus on high sensitivity and throughput solutions [3][10][12] Core Product Innovations 1. **TIMS Ultra and AIP**: - New product launched to enhance MSMS sensitivity and bandwidth, allowing for more peptides and proteins to be analyzed [5][7] - Significant advancements in single-cell proteomics, enabling analysis of smaller cells than previously possible [8] 2. **TIMS Metabo Instrument**: - Aimed at the high-resolution accurate mass market for small molecules, targeting applications in PFAS research, toxicology, and metabolomics [11][12] - Expected to double the market opportunity for Bruker, potentially reaching a $200 million market share [15] 3. **TIMS Omni**: - A revolutionary mass spectrometer combining TIMS technology with Omni Trap, enabling top-down proteomics and functional proteomics [17][18] - Positioned to create a new category in mass spectrometry with no direct competition [19] Financial Outlook - **Revenue Guidance**: Anticipated moderate growth in 2026, with expectations of organic growth between 6% to 8% [32] - **Cost Management**: Bruker is implementing cost-cutting measures, including reducing operational costs in European sites and optimizing R&D spending [33][35] Market Dynamics - **Academic Market**: Anticipated decline in academic spending by 20-25% due to budget constraints, impacting overall revenue [22][30] - **Defense and Homeland Security**: Notable growth in the detection business for radiological and chemical threats, with potential revenue increases of $20 million next year [38][39] Emerging Markets and Opportunities - **Semiconductor and AI**: Strong demand in metrology for high-performance computing and AI applications, expected to grow from 8% to potentially 12% of total revenue [45][46] - **China Market**: Potential for stimulus-driven growth in high-end research tools, although timing remains uncertain [51][52] Strategic Developments - **Cell Analysis and Diagnostics**: Launch of a new benchtop product aimed at broadening market access for antibody discovery and cell line selection [54][55] - **Spatial Biology**: Continued investment in spatial biology technologies, enhancing capabilities in multi-omics and improving throughput and detection efficiency [61][62] Conclusion - Bruker is positioned for growth through innovative product offerings in mass spectrometry and proteomics, despite facing challenges in academic funding and market uncertainties. The company is strategically focusing on high-growth areas such as biopharma, diagnostics, and advanced manufacturing technologies.

转自：前瞻产业研究院 本文核心数据：全球精准非靶标代谢组学市场规模;中国精准非靶标代谢组学应用占比;中国精准非靶标 代谢组学市场规模;企业市占率等 精准非靶标代谢组学的概述 代谢组是指一个细胞、组织器官或生物体中所有参与生物体代谢、维持正常功能和生长发育的小分子化 合物的集合，包括糖类、核苷、有机酸、酮类化合物、多肽、氨基酸、有机胺类、醛类化合物、脂质、 萜类、类固醇、生物碱、小分子药物等等。 代谢组学主要通过考察生物体系在某一特定时期内或受到刺激或扰动前后，所有小分子代谢物(分子量 小于1500 Da)的组成及含量变化，寻找代谢物与生理病理变化的相对关系，主要通过组群指标分析、高 通量检测、数据处理、信息建模、系统整合等技术完成分析。 精准非靶标代谢组学是在传统代谢组学基础上结合高通量技术检测平台、精准代谢组学、多组学等技 术，进一步拓展和深化应用，更好地应用于精准医疗、生物标志物发现等场景。 国内精准非靶标代谢组学服务主要有百趣生物的新一代代谢组学、中科新生命的非靶代谢组plus、诺禾 致源的非靶向代谢组学、欧易生物的Level One 500全谱代谢组以及迈特维尔的TM广靶代谢组服务。新 一代代谢组学是 ...

Market Overview - The market experienced a weak fluctuation, with all three major indices closing down. The consumer sector showed resilience, while over 3,800 stocks declined [1][3] - Goldman Sachs raised the 12-month targets for the MSCI China Index and the CSI 300 Index to 84 points and 4,600 points, respectively, indicating potential upside of 11% and 17%. They maintain an overweight rating on Chinese stocks and suggest focusing on multiple themes for excess returns [1] Sector Performance - New hotspots emerged in the market, particularly in the ergot sulfur concept, with Chuaning Biological hitting a 20% limit up. Other sectors such as beauty care and medical aesthetics also saw significant gains [1] - The food and beverage sector rebounded in the afternoon, with several stocks, including Xiwang Food, hitting the limit up. The shipping and port sector continued its upward trend, with Nanjing Port achieving three consecutive limit ups [1] - The textile and apparel sector showed recovery, with Huafang Co. achieving six limit ups in eight days. Other sectors like coal, chemicals, synthetic biology, rare earths, and ST stocks also performed well [1] Individual Stock Movements - A total of 1,407 stocks rose, while 3,856 stocks fell, with 149 stocks remaining flat. There were 78 stocks hitting the limit up and 12 stocks hitting the limit down [3] - The Shanghai Composite Index fell by 0.68% to 3,380.82 points, with a trading volume of 461.3 billion yuan. The Shenzhen Component Index dropped by 1.62% to 10,186.45 points, with a trading volume of 688.7 billion yuan. The ChiNext Index decreased by 1.91% to 2,043.25 points [3] Fund Flow - Main funds focused on sectors such as chemical pharmaceuticals, small metals, and passenger vehicles, with notable net inflows into stocks like BYD, Chuaning Biological, and Shenghe Resources [4] Regulatory Developments - The China Securities Regulatory Commission (CSRC) is expediting the introduction of a comprehensive policy package to deepen reforms in the Sci-Tech Innovation Board and the ChiNext, aiming to enhance the inclusiveness and adaptability of the system [5] Industry Insights - The anti-aging industry is divided into medical and non-medical tracks, with the former focusing on basic medical research and the latter encompassing various fields such as sociology and artificial intelligence [2] - The China Academy of Sciences has made breakthroughs in the electro-catalytic reforming of waste plastic PET to produce biodegradable plastic PGA, with projected market demand reaching millions of tons [6] Economic Outlook - Analysts from Minsheng Securities suggest that China's asset resilience may be higher than that of overseas markets, with a focus on consumption sectors and undervalued financial stocks [9] - Huazhong Securities indicates that the market will continue to experience fluctuations until significant improvements in the macroeconomic fundamentals are observed [10]